Department of Radiation Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Département de Médecine Nucléaire et Radiobiologie, Université de Sherbrooke, Sherbrooke, Quebec J1K 2R1, Canada.
Mol Ther. 2022 Mar 2;30(3):1149-1162. doi: 10.1016/j.ymthe.2021.11.011. Epub 2021 Nov 15.
STAT3 signaling has been shown to regulate cellular function and cytokine production in the tumor microenvironment (TME). Within the head and neck squamous cell carcinoma (HNSCC) TME, we previously showed that therapeutic targeting of STAT3 in combination with radiation resulted in improved tumor growth delay. However, given the independent regulatory effects STAT3 has on anti-tumor immunity, we aimed to decipher the effects of individually targeting STAT3 in the cancer cell, regulatory T cells (Tregs), and natural killer (NK) cell compartments in driving tumor growth and resistance to therapy in HNSCCs. We utilized a CRISPR knockout system for genetic deletion of STAT3 within the cancer cell as well as two genetic knockout mouse models, FoxP3-Cre/STAT3 fl and NKp46-Cre/STAT3 fl, for Tregs and NK cell targeting, respectively. Our data revealed differences in development of resistance to treatment with STAT3 CRISPR knockout in the cancer cell, driven by differential recruitment of immune cells. Knockout of STAT3 in Tregs overcomes this resistance and results in Treg reprogramming and recruitment and activation of antigen-presenting cells. In contrast, knockout of STAT3 in the NK cell compartment results in NK cell inactivation and acceleration of tumor growth. These data underscore the complex interplay between the cancer cell and the immune TME and carry significant implications for drug targeting and design of combination approaches in HNSCCs.
STAT3 信号已被证明可调节肿瘤微环境(TME)中的细胞功能和细胞因子产生。在头颈部鳞状细胞癌(HNSCC)的 TME 中,我们之前曾表明,联合放射治疗靶向 STAT3 可改善肿瘤生长延迟。然而,鉴于 STAT3 对抗肿瘤免疫具有独立的调节作用,我们旨在阐明单独靶向 STAT3 在癌细胞、调节性 T 细胞(Tregs)和自然杀伤(NK)细胞区室中对驱动肿瘤生长和 HNSCC 治疗耐药的影响。我们利用 CRISPR 敲除系统在癌细胞中对 STAT3 进行基因缺失,以及两种基因敲除小鼠模型 FoxP3-Cre/STAT3 fl 和 NKp46-Cre/STAT3 fl,分别用于 Tregs 和 NK 细胞靶向。我们的数据揭示了在癌症细胞中,通过招募不同的免疫细胞,对 STAT3 CRISPR 敲除治疗的耐药性存在差异。在 Tregs 中敲除 STAT3 可克服这种耐药性,并导致 Treg 重编程以及抗原呈递细胞的募集和激活。相比之下,在 NK 细胞区室中敲除 STAT3 会导致 NK 细胞失活并加速肿瘤生长。这些数据强调了癌细胞与免疫 TME 之间的复杂相互作用,并对 HNSCC 中的药物靶向和联合治疗方法的设计具有重要意义。